

Accreditation and Designation Statements and Disclosure Report

LUGPA 2026 Global Prostate Cancer Congress

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute and the LUGPA. PeerPoint Medical Education Institute is accredited by the ACCME to provide continuing medical education for physicians.

PeerPoint Medical Education Institute designates the live and enduring formats for this educational activity for a maximum of *9.25 AMA PRA Category 1 Credits™*. Physicians should only claim credit commensurate with the extent of their participation in the activities.

The live approval period is: January 10-13, 2026

The enduring approval period is: February 10, 2026 – February 10, 2029

Financial Disclosures.

The following planners, speakers, reviewers or staff have relevant financial relationships to disclose:

“I have at present or have had within the last 24 months, a financial relationship with one or more ineligible companies.”

Full Legal Name	Commercial Interest	Role	Level of participation in the activity
David Albala	Applied Medical	Stock/Stock Options	Speaker
	MDx Health	Researcher/Investigator	
Marijo Bilusic	Bicycle Therapeutics, Pfizer, Clasp Therapeutics, Hookipa Pharma, Eli Lilly, Marengo Therapeutics, Surface Oncology, Merck Sharp & Dohme,	Research Funding	Speaker
Renee Cherry	Tolmar	Consultant	Speaker
Matthew Cooperberg	Exosome, Astellas Amgen, Janssen, Veracyte, GSK, Pfizer, LynxDx	Consultant	Speaker
Jason Efstathiou	Boston Scientific, Bioprotect, Astellas/Pfizer, MDxHealth, Clarity Pharmaceuticals	Consultant	Speaker
	Janssen/Johnson & Johnson	Advisor	

Scott Eggener	A3P biomedical, Janssen Candel Therapeutics	Consultant Researcher/Investigator	Speaker
Jason Hafron	Novartis, Urogen, Bayer, Myriad, Dendreon, Janssen Biotech, Astellas, Immunis AI Scientific, AZ, Merck, Photcure, Lilly, ArteraAI, Sumitomo	Consultant Researcher/Investigator Speaker	Speaker
Ron Kaufman	Clarity, Ferring. SUO-CTC- ECOG-ACRIN, Stebabiotech, Bection, Dickison & Company, Pacific Edge Diagnostics, enGene, Janssen	Research Funding	Speaker
Michael Liss	Oncobiomix	Ownership Interest	Speaker
Benjamin Lowentritt	Pfizer, Sumitomo Pharma, Astellas, Merck, AstraZeneca, Bayer Johnson & Johnson, Cencora Specialty Networks Dendreon, Novartis	Advisor Consultant Ownership Interest Researcher/Investigator	Speaker
Travis Mendel	GE, Novartis	Advisor	Speaker
Todd Morgan	Pfizer, Johnson & Johnson, Merck, Foundation Medicine	Researcher/Investigator Consultant	Speaker
David Morris	Pfizer, Merck, AZ, Bayer, Dendreon, Decipher, Telix, Johnson & Johnson, Caris, Sumitomo, Veritas, Astellas	Consultant	Speaker. Planner/Reviewer
Diane Newman	NIH, Hollister	Researcher/Investigator	Speaker
Scott Sellinger	Sumitomo, COSM, Innocare, Convatec, Urology Health Grand Rounds in Urology Avyxa, Astellas, Sumitomo, Bayer, Foundation Medicine, Tempus, MDX Health, Accord Biopharma, AZ, Johnson & Johnson, Pfizer	Advisor Editor Consultant	Speaker, Planner/Reviewer

These financial relationship(s) with ineligible companies have been mitigated by PeerPoint Medical Education Institute and the LUPGA.

All other presenters, planners, editors, or staff report no relationships to disclose:

"I do not have at present nor have had within the last 24 months, any financial relationships with ineligible companies."